Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 15/20 | 1.00 |
| ▸ | CCNH | P51946 | 15/20 | 1.00 |
| ▸ | CCNK | O75909 | 13/20 | 1.00 |
| ▸ | CDK12 | Q9NYV4 | 13/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 11/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 10/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 10/20 | 1.00 |
| ▸ | CDK2 | P24941 | 10/20 | 1.00 |
| ▸ | CDK9 | P50750 | 10/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sy-5609 SCHEMBL22076285 | 1.00 | CDK7 (1.00) | CDK7CCNHCCNKCDK12MNAT1 | |
| Sy-5609 SCHEMBL22076284 | 1.00 | CDK7 (1.00) | CDK7CCNHCCNKCDK12MNAT1 | |
| SCHEMBL24308148 | 0.93 | CCNK (0.86) | CDK7CCNHCCNKCDK12MNAT1 | |
| SCHEMBL25593809 | 0.93 | CDK7 (0.86) | CDK7CCNHCCNKCDK12MNAT1 | |
| SCHEMBL25593099 | 0.92 | CCNK (0.85) | CDK7CCNHCCNKCDK12MNAT1 | |
| SCHEMBL24588082 | 0.89 | CDK7 (0.81) | CDK7CCNHCCNKCDK12MNAT1 | |
| SCHEMBL24588870 | 0.88 | CDK7 (0.79) | CDK7CCNHCCNKCDK12MNAT1 | |
| SCHEMBL24588122 | 0.88 | CDK7 (0.79) | CDK7CCNHCCNKCDK12MNAT1 | |
| SCHEMBL26327182 | 0.88 | CDK7 (0.79) | CDK7CCNHCCNKCDK12MNAT1 | |
| SCHEMBL22076294 | 0.88 | CCNK (0.79) | CDK7CCNHCCNKCDK12MNAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695235-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | Cyrus Therapeutics Inc. (KR) | 2026-02-18 | — | — | EP | claimed |
| US-20250367222-A1 | TREATMENTS FOR CANCERS DRIVEN BY DNAJB1-PRKACA GENE FUSIONS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-12-04 | — | — | US | claimed |
| US-20250221989-A1 | PHARMACEUTICAL COMPOSITION, USE THEREOF, AND METHOD FOR TREATING CANCER | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2025-07-10 | — | — | US | claimed |
| EP-4529926-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | Ascentawits Pharmaceuticals, Ltd. (CN) | 2025-04-02 | — | — | EP | claimed |
| EP-4506004-A1 | PHARMACEUTICAL COMPOSITION, USE THEREOF, AND METHOD FOR TREATING CANCER | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2025-02-12 | — | — | EP | claimed |
| CN-119233822-A | Methods of treating cancer using alkylating agent prodrugs and cell cycle inhibitors in combination | 深圳艾欣达伟医药科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| WO-2024215130-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | CYRUS THERAPEUTICS INC. (KR) | 2024-10-17 | — | — | WO | claimed |
| WO-2023226959-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | 深圳艾欣达伟医药科技有限公司 | 2023-11-30 | — | — | WO | claimed |
| WO-2023186075-A1 | PHARMACEUTICAL COMPOSITION, USE THEREOF, AND METHOD FOR TREATING CANCER | 劲方医药科技(上海)有限公司 | 2023-10-05 | — | — | WO | claimed |
| CN-116327956-A | Pharmaceutical composition, use thereof and method for treating cancer | 劲方医药科技(上海)有限公司 | 2023-06-27 | — | — | CN | claimed |
| US-20220288067-A1 | TREATMENT OF CANCER WITH CDK INHIBITORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-09-15 | — | — | US | claimed |
| EP-4695235-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | Cyrus Therapeutics Inc. (KR) | 2026-02-18 | — | — | EP | disclosed |
| EP-4658641-A1 | NOVEL COMPOUNDS THAT CAN BE USED AS THERAPEUTIC AGENTS | Xeniom GmbH (DE) | 2025-12-10 | — | — | EP | disclosed |
| US-20250367222-A1 | TREATMENTS FOR CANCERS DRIVEN BY DNAJB1-PRKACA GENE FUSIONS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250283178-A1 | FOXC1 EXPRESSION AS A COMPLEMENTARY DIAGNOSTIC ASSAY FOR PREDICTING EFFICACY OF ONCOLOGY DRUGS AND DRUG COMBINATION REGIMENS AND METHODS FOR USE | 3N DIAGNOSTICS LTD. (GB) | 2025-09-11 | — | — | US | disclosed |
| CN-115819406-B | Synthesis method of 3- (4-pyrimidine) -1H-indole compound | 淄博百极荣创医药科技有限公司 | 2023-06-02 | — | — | CN | disclosed |
| WO-2023040998-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2023-03-23 | — | — | WO | disclosed |
| CN-115819406-A | Synthetic method of 3- (4-pyrimidine) -1H-indole compound | 淄博百极荣创医药科技有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-115583946-A | Heterocyclic compounds and their use as CDK inhibitors | 赛诺哈勃药业（成都）有限公司 | 2023-01-10 | — | — | CN | disclosed |
| US-20220288067-A1 | TREATMENT OF CANCER WITH CDK INHIBITORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221989-A1 | PHARMACEUTICAL COMPOSITION, USE THEREOF, AND METHOD FOR TREATING CANCER | KRAS, NRAS, HRAS | CDK7 133/4885CCNH 373/4885CCNK 156/4885 |
| US-20220288067-A1 | TREATMENT OF CANCER WITH CDK INHIBITORS | CDK3, CDK4, CDK1 | CDK7 18/4885CCNH 21/4885CCNK 8/4885 |
| US-20250367222-A1 | TREATMENTS FOR CANCERS DRIVEN BY DNAJB1-PRKACA GENE FUSIONS | CDK9, CDC73, CDK4 | CDK7 10/4885CCNH 185/4885CCNK 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.